{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:37:37Z","timestamp":1793342257444,"version":"4.5.0"},"reference-count":94,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon subtype of mature peripheral T-cell lymphoma (PTCL). The history of AITL is much longer and deeper than the literature would suggest given the many names that have preceded it. Advanced-stage disease is common with uncharacteristic laboratory and autoimmune findings that often slow or mask the diagnosis. Significant strides in the immunohistochemical and molecular signature of AITL have brought increased ability to diagnose this uncommon type of PTCL. The 2016 World Health Organization classification of lymphoid neoplasms recently acknowledged the complexity of this diagnosis with the addition of other AITL-like subsets. AITL now resides under the umbrella of nodal T-cell lymphomas with follicular T helper phenotype. Induction strategies continue to focus on increasing complete remission rates that allow more transplant-eligible patients to proceed toward consolidative high-dose therapy and autologous stem cell rescue with improving long-term survival. There are several clinical trials in which recently approved drugs with known activity in AITL are paired with induction regimens with the hope of demonstrating long-term progression-free survival over cyclophosphamide, doxorubicin, vincristine, and prednisone. The treatment of relapsed or refractory AITL remains an unmet need. The spectrum of AITL from diagnosis to treatment is reviewed subsequently in a fashion that may one day lead to personalized treatment approaches in a many-faced disease.<\/jats:p>","DOI":"10.1182\/blood-2016-09-692541","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T02:55:15Z","timestamp":1485226515000},"page":"1095-1102","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":188,"title":["Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma"],"prefix":"10.1182","volume":"129","author":[{"given":"Matthew A.","family":"Lunning","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111903370728700_B1","author":"Swerdlow"},{"issue":"20","key":"2019111903370728700_B2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111903370728700_B3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0002-9343(75)90466-0","article-title":"Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course","volume":"59","author":"Frizzera","year":"1975","journal-title":"Am J Med"},{"issue":"1","key":"2019111903370728700_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM197501022920101","article-title":"Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin\u2019s disease","volume":"292","author":"Lukes","year":"1975","journal-title":"N Engl J Med"},{"issue":"35","key":"2019111903370728700_B5","first-page":"1246","article-title":"[Nature, prognosis and nomenclature of angioimmunoblastic lymphadenopathy (lymphogranulomatosis X or T-zone lymphoma)]","volume":"104","author":"Lennert","year":"1979","journal-title":"Dtsch Med Wochenschr"},{"issue":"7","key":"2019111903370728700_B6","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V79.7.1789.1789","article-title":"Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma","volume":"79","author":"Weiss","year":"1992","journal-title":"Blood"},{"issue":"3","key":"2019111903370728700_B7","first-page":"549","article-title":"Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy","volume":"133","author":"Feller","year":"1988","journal-title":"Am J Pathol"},{"issue":"2","key":"2019111903370728700_B8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.V72.2.413.413","article-title":"Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive \u201cangioimmunoblastic lymphadenopathy with dysproteinemia-type\u201d features","volume":"72","author":"Kaneko","year":"1988","journal-title":"Blood"},{"issue":"3","key":"2019111903370728700_B9","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1182\/blood.V72.3.1000.1000","article-title":"Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma","volume":"72","author":"Tobinai","year":"1988","journal-title":"Blood"},{"issue":"2","key":"2019111903370728700_B10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111903370728700_B11","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111903370728700_B12","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111903370728700_B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S0036-46652015000100001","article-title":"Origin and prevalence of human T-lymphotropic virus type 1 (HTLV-1) and type 2 (HTLV-2) among indigenous populations in the Americas","volume":"57","author":"Paiva","year":"2015","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"5","key":"2019111903370728700_B14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MD.0b013e3181573059","article-title":"Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients","volume":"86","author":"Lachenal","year":"2007","journal-title":"Medicine (Baltimore)"},{"issue":"5-6","key":"2019111903370728700_B15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/10428199909058412","article-title":"Angioimmunoblastic-like T-cell non Hodgkin\u2019s lymphoma: outcome after chemotherapy in 33 patients and review of the literature","volume":"32","author":"Pautier","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111903370728700_B16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"2019111903370728700_B17","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3109\/10428194.2013.767901","article-title":"18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma","volume":"54","author":"Casulo","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111903370728700_B18","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1309\/AJCPQXKCHQH4VAJ5","article-title":"Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement","volume":"131","author":"Cho","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"2019111903370728700_B19","article-title":"Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group","volume-title":"Ann Oncol","author":"Siegert","year":"1995"},{"issue":"7","key":"2019111903370728700_B20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archderm.136.7.881","article-title":"Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy with dysproteinemia: a clinical, immunohistological, and molecular analysis","volume":"136","author":"Martel","year":"2000","journal-title":"Arch Dermatol"},{"issue":"7","key":"2019111903370728700_B21","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/PAS.0b013e31802df4ef","article-title":"Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL)","volume":"31","author":"Ortonne","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2019111903370728700_B22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","article-title":"Advances in the understanding and management of angioimmunoblastic T-cell lymphoma","volume":"148","author":"de Leval","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111903370728700_B23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1046\/j.1365-2141.2003.04335.x","article-title":"Angioimmunoblastic T-cell lymphoma","volume":"121","author":"Dogan","year":"2003","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111903370728700_B24","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1200\/JCO.2012.43.3797","article-title":"Angioimmunoblastic T-cell lymphoma partially obscured by an Epstein-Barr virus-negative clonal plasma cell proliferation","volume":"31","author":"Huppmann","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111903370728700_B25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/sj.leu.2404013","article-title":"Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma. Leukemia: official journal of the Leukemia Society of America","volume":"20","author":"Baseggio","year":"2006","journal-title":"Leukemia."},{"issue":"12","key":"2019111903370728700_B26","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.3109\/10428194.2016.1170827","article-title":"Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology","volume":"57","author":"Loghavi","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2019111903370728700_B27","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111903370728700_B28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nri1714","article-title":"Follicular B helper T cells in antibody responses and autoimmunity","volume":"5","author":"Vinuesa","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2019111903370728700_B29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V99.2.627","article-title":"Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10","volume":"99","author":"Attygalle","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2019111903370728700_B30","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2007.06725.x","article-title":"Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases","volume":"138","author":"Willenbrock","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111903370728700_B31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2141.2007.06620.x","article-title":"Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load","volume":"138","author":"Zhou","year":"2007","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111903370728700_B32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.humpath.2005.05.008","article-title":"CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry","volume":"36","author":"Yuan","year":"2005","journal-title":"Hum Pathol"},{"issue":"1","key":"2019111903370728700_B33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00428-004-1114-1","article-title":"In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study","volume":"446","author":"Willenbrock","year":"2005","journal-title":"Virchows Arch"},{"issue":"2","key":"2019111903370728700_B34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","article-title":"Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases","volume":"58","author":"Karube","year":"2008","journal-title":"Pathol Int"},{"issue":"8","key":"2019111903370728700_B35","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"2019111903370728700_B36","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2005-03-1083","article-title":"Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?","volume":"106","author":"Grogg","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2019111903370728700_B37","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells","volume":"30","author":"Dupuis","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2019111903370728700_B38","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2019111903370728700_B39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PAS.0b013e31820065c9","article-title":"CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma","volume":"35","author":"Dorfman","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2019111903370728700_B40","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3324\/haematol.2009.010991","article-title":"The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation","volume":"95","author":"Marafioti","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"2019111903370728700_B41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.pai.0000173053.45296.51","article-title":"Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma","volume":"13","author":"Troxell","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"2019111903370728700_B42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/gcc.20386","article-title":"Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach","volume":"46","author":"Thorns","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"2019111903370728700_B43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2008.07042.x","article-title":"Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma","volume":"141","author":"Nelson","year":"2008","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111903370728700_B44","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/labinvest.3780382","article-title":"Alterations on the 5\u2032 noncoding region of the BCL-6 gene are not correlated with BCL-6 protein expression in T cell non-Hodgkin lymphomas","volume":"81","author":"Kerl","year":"2001","journal-title":"Lab Invest"},{"issue":"2","key":"2019111903370728700_B45","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0002-9440(10)64770-0","article-title":"Frequent T and B cell oligoclones in histologically and immunophenotypically characterized angioimmunoblastic lymphadenopathy","volume":"156","author":"Smith","year":"2000","journal-title":"Am J Pathol"},{"issue":"24","key":"2019111903370728700_B46","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2012.42.5611","article-title":"Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study","volume":"31","author":"Piccaluga","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111903370728700_B47","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111903370728700_B48","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111903370728700_B49","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111903370728700_B50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111903370728700_B51","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111903370728700_B52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"2019111903370728700_B53","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"issue":"8","key":"2019111903370728700_B54","first-page":"1038","article-title":"Molecular mechanisms of angioimmunoblastic T-cell lymphoma development","volume":"57","author":"Sakata-Yanagimoto","year":"2016","journal-title":"Rinsho Ketsueki"},{"issue":"1","key":"2019111903370728700_B55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.onc.1203259","article-title":"Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma","volume":"19","author":"Cleverley","year":"2000","journal-title":"Oncogene"},{"issue":"5","key":"2019111903370728700_B56","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-117-5-364","article-title":"Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM\/IMVP-16 regimen. A multicenter study","volume":"117","author":"Siegert","year":"1992","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019111903370728700_B57","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.seminhematol.2013.11.008","article-title":"Angioimmunoblastic T-cell lymphoma management","volume":"51","author":"Mosalpuria","year":"2014","journal-title":"Semin Hematol"},{"issue":"2","key":"2019111903370728700_B58","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"issue":"25","key":"2019111903370728700_B59","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111903370728700_B60","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111903370728700_B61","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"key":"2019111903370728700_B62","article-title":"Safe and effective treatment of patients with peripheral T-cell lymphoma (PTCL) with the novel HDAC inhibitor, belinostat, in combination with CHOP: results of the Bel-CHOP phase I trial [abstract]","volume-title":"Blood","author":"Johnston"},{"issue":"13","key":"2019111903370728700_B63","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"issue":"17","key":"2019111903370728700_B64","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"issue":"15, suppl","key":"2019111903370728700_B65","first-page":"5884","article-title":"A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial [abstract]","volume":"27","author":"Delmer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111903370728700_B66","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","article-title":"NCCN guidelines insights: non-Hodgkin\u2019s lymphomas, version 3.2016","volume":"14","author":"Horwitz","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2019111903370728700_B67","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"2019111903370728700_B68","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111903370728700_B69","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/10428194.2013.816700","article-title":"Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)","volume":"55","author":"Ganjoo","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111903370728700_B70","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3109\/10428194.2011.623256","article-title":"Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial","volume":"53","author":"Advani","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2019111903370728700_B71","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","article-title":"Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA","volume":"97","author":"Delfau-Larue","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"2019111903370728700_B72","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111903370728700_B73","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019111903370728700_B74","author":"Kluin-Nelemans","year":"2011"},{"issue":"6","key":"2019111903370728700_B75","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111903370728700_B76","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"issue":"16","key":"2019111903370728700_B77","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2012.48.3883","article-title":"Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve","volume":"31","author":"Lunning","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111903370728700_B78","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111903370728700_B79","first-page":"1272","article-title":"Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig","year":"2003","journal-title":"Haematologica"},{"issue":"16","key":"2019111903370728700_B80","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111903370728700_B81","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1600-0609.2004.00294.x","article-title":"ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience","volume":"73","author":"Jerkeman","year":"2004","journal-title":"Eur J Haematol"},{"key":"2019111903370728700_B82","author":"Zelenetz","year":"2003"},{"issue":"7","key":"2019111903370728700_B83","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood.V77.7.1587.1587","article-title":"Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation","volume":"77","author":"Philip","year":"1991","journal-title":"Blood"},{"issue":"1","key":"2019111903370728700_B84","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"issue":"2","key":"2019111903370728700_B85","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"2019111903370728700_B86","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3816\/CLM.2005.n.030","article-title":"A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-Cell and T-Cell non-Hodgkin\u2019s lymphoma","volume":"6","author":"Crump","year":"2005","journal-title":"Clin Lymphoma"},{"issue":"1","key":"2019111903370728700_B87","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111903370728700_B88","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1182\/blood.V106.11.2679.2679","article-title":"Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed\/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat [abstract]","volume":"106","author":"Horwitz","year":"2005","journal-title":"Blood"},{"issue":"25","key":"2019111903370728700_B89","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111903370728700_B90","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111903370728700_B91","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"23","key":"2019111903370728700_B92","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111903370728700_B93","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111903370728700_B94","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leuk Lymphoma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/9\/1095\/1402386\/blood692541.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/9\/1095\/1402386\/blood692541.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T07:04:55Z","timestamp":1601449495000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/9\/1095\/36554\/Angioimmunoblastic-Tcell-lymphoma-the-manyfaced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,2]]},"references-count":94,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,3,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-09-692541","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,2]]}}}